Biotech Values

[WorstLuck]

Dumping the US rights looked like an obvious decision, and trying to use the material breach clause to accelerate the termination tells me they thought International was obvious as well, in spite of applications in process at EMA and elsewhere.

Complete write-off. I haven't found Vada sales numbers by MTPC in Japan (haven't looked that hard) but they haven't been good enough to make them easy to find.

Yeah, they were off about 20% but that is only about a dime, so....

As an afterthought - it remains to be seen what Astra does with the US rights for Roxa. Doing well in China and Astellas is getting approvals in it's territories.